Trial · NCT03764241
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
NCT03764241, Phase 3, Unknown, RenJi Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant. Trials, record NCT03764241. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03764241
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
- NCT number
- NCT03764241
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 280 participants, estimated
- Lead sponsor
- RenJi Hospital
- Conditions
- ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
- Interventions
- Rivaroxaban, Vitamin K Antagonist
- First posted
- 2018-12-05
- Last updated
- 2023-06-01
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of LVT resolution after triple antithrombotic therapy for 3 month | 3 months | The LVT resolve will be determined monthly by follow-up imaging examination (CMR or TTE). The percentage of LVT resolve at 3 months will be calculated for each group. |
| Primary | Major bleeding events (ISTH criteria) through the study, an average of 12 weeks | Through the study, an average of 12 weeks | Major Bleeding events will be classified by the ISTH criteria.It is defined as clinically over bleeding that is associated with: 1. A fall in hemoglobin of 2g/dL or more or 2.A transfusion of 2 or more units of packed red blood cells or whole blood, or 3.A critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retropertioneal, or 4. A fatal outcome. All bleeding events will be documented through the study, an average of 12weeks |
| Secondary | Composite major adverse events through the study, an average of 3 months and 1 year | Through study completion, an average of 3 months and 1 year | The incidence of a composite adverse events, including all-cause death, recurrent myocardial infarction, ischemic stroke and other systemic embolism through 3 months and 1 year will be calculated for each group. |
| Secondary | Non-major bleeding events (ISTH criteria) through the study, an average of 3 months and 1 year | Through study completion, an average of 3 months and 1 year | Non-major bleeding events is identified by ISTH ctiteria. |
| Secondary | Time to LVT resolution | from LVT detected to LVT resolution | The time from LVT detected to LVT resolution |
| Secondary | Incidence of any systemic embolic events within 3 months and 1 year | within 3 months and 1 year | Incidence of any systemic embolic events within 3 months and 1 year after triple therapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers17
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03764241
GET https://conductscience.org/api/trials/v1/NCT03764241/registered